Chen Si-Yu, Kong Xiang-Quan, Zhang Ke-Fan, Luo Shuai, Wang Feng, Zhang Jun-Jie
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
Department of Cardiology, Nanjing Heart Centre, Nanjing, People's Republic of China.
J Inflamm Res. 2022 Sep 16;15:5457-5469. doi: 10.2147/JIR.S380285. eCollection 2022.
The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy.
心血管疾病患病率的不断上升已成为全球健康问题。心血管疾病的发生是多种危险因素长期相互作用的结果,其中之一就是糖尿病。作为一种新型抗糖尿病药物,二肽基肽酶4(DPP4)抑制剂在最近完成的五项心血管结局试验中已被证明具有心血管安全性。越来越多的研究表明,DPP4抑制剂在包括高血压、钙化性主动脉瓣疾病、冠状动脉粥样硬化和心力衰竭在内的多种心血管疾病中具有潜在益处。一方面,DPP4抑制剂除了改善血糖控制外,还参与控制心血管危险因素。另一方面,DPP4抑制剂通过多种机制直接调节心血管疾病的发生和发展。在这篇综述中,我们总结了DPP4在心血管疾病方面的最新进展,旨在探讨DPP4抑制剂作为心血管治疗的一种潜在选择。